Xeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimer

Equities research analysts at Oppenheimer initiated coverage on shares of Xeris Biopharma (NASDAQ:XERS) in a report released on Thursday, Marketbeat reports. The brokerage set an “outperform” rating and a $5.00 price target on the stock. Oppenheimer’s target price suggests a potential upside of 145.10% from the company’s current price.

Separately, HC Wainwright boosted their price objective on Xeris Biopharma from $5.50 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, March 7th.

Xeris Biopharma Stock Down 0.5 %

Shares of XERS opened at $2.04 on Thursday. The company has a debt-to-equity ratio of 49.27, a quick ratio of 1.23 and a current ratio of 1.64. Xeris Biopharma has a one year low of $1.26 and a one year high of $3.26. The stock has a market capitalization of $286.52 million, a price-to-earnings ratio of -4.53 and a beta of 2.37. The stock has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.19.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The firm had revenue of $44.39 million for the quarter, compared to analysts’ expectations of $45.50 million. Xeris Biopharma had a negative return on equity of 610.76% and a negative net margin of 37.98%. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. Equities research analysts forecast that Xeris Biopharma will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds have recently modified their holdings of the business. Shay Capital LLC purchased a new position in Xeris Biopharma during the 1st quarter valued at about $34,000. China Universal Asset Management Co. Ltd. boosted its holdings in Xeris Biopharma by 351.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,973 shares of the company’s stock valued at $38,000 after acquiring an additional 12,432 shares during the period. Osaic Holdings Inc. boosted its holdings in Xeris Biopharma by 50.4% during the 2nd quarter. Osaic Holdings Inc. now owns 16,407 shares of the company’s stock valued at $43,000 after acquiring an additional 5,500 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Xeris Biopharma by 309.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 18,115 shares of the company’s stock valued at $34,000 after acquiring an additional 13,688 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Xeris Biopharma in the 3rd quarter valued at about $34,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.